Testing Investigational Treatments That Target Tau
The Alzheimer’s Tau Platform (ATP) Study is testing investigational treatments that target tau, a protein linked to Alzheimer’s disease. By participating, you can help researchers learn more about Alzheimer’s disease and potential treatments.
Who can participate?
Adults 50–80 years old who may be in the earliest biological stages of Alzheimer’s disease may be eligible. You do not need to have a diagnosis or noticeable memory or thinking problems to be considered for the study.
What is the ATP Study?
The ATP Study is a clinical trial evaluating investigational treatments that target tau alone or in combination with anti-amyloid treatment. Researchers will study changes in participants over time to learn more about the effects of these treatments, including when they are used together with amyloid-lowering treatments.
Why are researchers studying tau?
Alzheimer’s disease is associated with the buildup and accumulation of sticky clumps of two proteins in the brain: amyloid and tau.
- Amyloid builds up in the brain and forms amyloid plaques. These plaques can build up years or even decades before changes in memory and thinking occur.
- Tau can build up inside brain cells in what are called tangles. These tangles are closely linked to changes in memory and thinking.
- Amyloid plaques are believed to promote the formation of tau tangles.
Learning more about tau may help researchers better understand its role in Alzheimer’s disease.